Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 janv. 2023 08h00 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...
28 sept. 2022 16h09 HE | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Acquires Aceragen

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00...
05 nov. 2017 08h30 HE | Source: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting

HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel...